Impact of Chronic Anticholesterol Therapy on Development of Microvascular Rarefaction in the Metabolic Syndrome

References

• Barbato JE, Zuckerbraun BS, Overhaus M, Raman KG, Tzeng E. (2005). Nitric oxide modulates vascular inflammation and intimal hyperplasia in insulin resistance and the metabolic syndrome. Am J Physiol Heart Circ Physiol 289:H228–H236.
   Google Scholar
• Baumbach GL, Hajdu MA. (1993). Mechanics and composition of cerebral arterioles in renal and spontaneously hypertensive rats. Hypertension 21:816–826.
   PubMed Web of Science ®Google Scholar
• Beckman JA, Creager MA. (2006). The nonlipid effects of statins on endothelial function. Trends Cardiovasc Med 16:156–162.
   Google Scholar
• Boodhwani M, Nakai Y, Voisine P, Feng J, Li J, Mieno S, . (2006). High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response. Circulation 114:I402–I408.
   Google Scholar
• Bray GA. (1977). The Zucker-fatty rat: a review. Fed Proc 36:148–153.
   PubMedGoogle Scholar
• Bucay M, Nguy J, Barrios R, Chen CH, Henry PD. (1998). Impaired adaptive vascular growth in hypercholesterolemic rabbit. Atherosclerosis 139:243–251.
   Google Scholar
• Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. (2005). Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111:1448–1454.
   PubMed Web of Science ®Google Scholar
• Davidson MH, Ose L, Frohlich J, Scott RS, Dujovne CA, Escobar ID, . (2003). Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups. Clin Cardiol 26:509–514.
   PubMedGoogle Scholar
• Duarte J, Martinez A, Bermejo A, Vera B, Gamez MJ, Cabo P, . (1999). Cardiovascular effects of captopril and enalapril in obese Zucker rats. Eur J Pharmacol 365:225–232.
   PubMed Web of Science ®Google Scholar
• Endres M. (2006). Statins: potential new indications in inflammatory conditions. Atheroscler Suppl 7:31–35.
   PubMed Web of Science ®Google Scholar
• Field KM. (2005). Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels. Pharmacotherapy 25:1365–1377.
   Google Scholar
• Frisbee JC, Balch Samora J, Peterson J, Bryner R. (2006). Exercise training blunts microvascular rarefaction in the metabolic syndrome. Am J Physiol Heart Circ Physiol 291:H2483–H2492.
   Google Scholar
• Frisbee JC. (2006). Impaired hemorrhage tolerance in the obese Zucker rat model of metabolic syndrome. J Appl Physiol 100:465–473.
   Google Scholar
• Frisbee JC. (2006). Vascular adrenergic tone and structural narrowing constrain reactive hyperemia in skeletal muscle of obese Zucker rats. Am J Physiol Heart Circ Physiol 290:H2066–H2074.
   Google Scholar
• Frisbee JC. (2005). Reduced nitric oxide bioavailability contributes to skeletal muscle microvessel rarefaction in the metabolic syndrome. Am J Physiol Regul Integr Comp Physiol 289:R307–R316.
   Google Scholar
• Frisbee JC. (2005). Hypertension-independent microvascular rarefaction in the obese Zucker rat model of the metabolic syndrome. Microcirculation 12:383–392.
   PubMed Web of Science ®Google Scholar
• Frisbee JC. (2004). Enhanced arteriolar alpha-adrenergic constriction impairs dilator responses and skeletal muscle perfusion in obese Zucker rats. J Appl Physiol 97:764–772.
   PubMedGoogle Scholar
• Frisbee JC. (2003). Impaired skeletal muscle perfusion in obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 285:R1124–R1134.
   Google Scholar
• Frisbee JC. (2003). Remodeling of the skeletal muscle microcirculation increases resistance to perfusion in obese Zucker rats. Am J Physiol Heart Circ Physiol 285:H104–H111.
   Google Scholar
• Ginsberg HN. (2006). Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab 91:383–392.
   PubMed Web of Science ®Google Scholar
• Greene AS, Lombard JH, Cowley AW, Jr, Hansen-Smith FM. (1990). Microvessel changes in hypertension measured by Griffonia simplicifolia I lectin. Hypertension 15:779–783.
   PubMed Web of Science ®Google Scholar
• Guerre-Millo M. (1997). Regulation of ob gene and overexpression in obesity. Biomed Pharmacother 51:318–323.
   Google Scholar
• Hardman JG, Limbird LE, Gilman AG. (2001). Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 10th. 971–1002. New York: McGraw-Hill.
   Google Scholar
• Hognestad A, Aukrust P, Wergeland R, Stokke O, Gullestad L, Semb AG, . (2004). Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation. Clin Cardiol 27:199–203.
   PubMedGoogle Scholar
• John S, Delles C, Jacobi J, Schlaich MP, Schneider M, Schmitz G, . (2001). Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol 37:1351–1358.
   PubMed Web of Science ®Google Scholar
• Knopp RH, Paramsothy P. (2006). Treatment of hypercholesterolemia in patients with metabolic syndrome: how do different statins compare?. Nat Clin Pract Endocrinol Metab 2:136–137.
   Google Scholar
• Laufs U, La Fata V, Plutzky J, Liao JK. (1998). Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97:1129–1135.
   PubMed Web of Science ®Google Scholar
• Libby P. (2002). Inflammation in atherosclerosis. Nature 420:868–874.
   PubMed Web of Science ®Google Scholar
• Lyon CJ, Law RE, Hsueh WA. (2003). Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 144:2195–2200.
   PubMed Web of Science ®Google Scholar
• Martinez-Gonzalez J, Alfon J, Berrozpe M, Badimon L. (2001). HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels. Atherosclerosis 159:27–33.
   PubMedGoogle Scholar
• Mason RP, Walter MF, Day CA, Jacob RF. (2005). Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol 96:11F–23F.
   PubMed Web of Science ®Google Scholar
• Picchi A, Gao X, Belmadani S, Potter BJ, Focardi M, Chilian WM, . Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ Res (2006);99:69–77.
   PubMed Web of Science ®Google Scholar
• Pirro M, Schillaci G, Savarese G, Gemelli F, Vaudo G, Siepi D, . (2004). Low-grade systemic inflammation impairs arterial stiffness in newly diagnosed hypercholesterolaemia. Eur J Clin Invest 34:335–341.
   PubMed Web of Science ®Google Scholar
• Ray KK, Cannon CP. (2005). The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 46:1425–1433.
   PubMed Web of Science ®Google Scholar
• Sasaki K, Duan J, Murohara T, Ikeda H, Shintani S, Shimada T, . (2003). Rescue of hypercholesterolemia-related impairment of angiogenesis by oral folate supplementation. J Am Coll Cardiol 42:364–372.
   PubMed Web of Science ®Google Scholar
• Sata M, Nishimatsu H, Osuga J, Tanaka K, Ishizaka N, Ishibashi S, . (2004). Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis. Hypertension 43:1214–1220.
   PubMed Web of Science ®Google Scholar
• Shige H, Dart A, Nestel P. (2001). Simvastatin improves arterial compliance in the lower limb but not in the aorta. Atherosclerosis 155:245–250.
   PubMed Web of Science ®Google Scholar
• Skaletz-Rorowski A, Walsh K. (2003). Statin therapy and angiogenesis. Curr Opin Lipidol 14:599–603.
   PubMed Web of Science ®Google Scholar
• Smilde TJ, van den Berkmortel FW, Wollersheim H, van Langen H, Kastelein JJ, Stalenhoef AF. (2000). The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia. Eur J Clin Invest 30:473–480.
   PubMed Web of Science ®Google Scholar
• Stokes KY. (2006). Microvascular responses to hypercholesterolemia: the interactions between innate and adaptive immune responses. Antioxid Redox Signal 8:1141–1151.
   PubMed Web of Science ®Google Scholar
• Theilmeier G, Verhamme P, Dymarkowski S, Beck H, Bernar H, Lox M, . (2002). Hypercholesterolemia in minipigs impairs left ventricular response to stress: association with decreased coronary flow reserve and reduced capillary density. Circulation 106:1140–1146.
   Google Scholar
• Tofovic SP, Jackson EK. (2003). Rat models of the metabolic syndrome. Meth Mol Med 86:29–46.
   PubMedGoogle Scholar
• Ubels FL, Muntinga JH, van Doormaal JJ, Reitsma WD, Smit AJ. (2001). Effects of initial and long-term lipid-lowering therapy on vascular wall characteristics. Atherosclerosis 154:155–161.
   Google Scholar
• Van Belle E, Rivard A, Chen D, Silver M, Bunting S, Ferrara N, . (1997). Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines. Circulation 96:2667–2674.
   PubMed Web of Science ®Google Scholar
• van Haelst PL, van Doormaal JJ, Asselbergs FW, van Roon AM, Veeger NJ, Henneman MM, . (2003). Correlates of endothelial function and their relationship with inflammation in patients with familial hypercholesterolaemia. Clin Sci (Lond) 104:627–632.
   Google Scholar
• Vaziri ND, Xu ZG, Shahkarami A, Huang KT, Rodriguez-Iturbe B, Natarajan R. (2005). Role of AT-1 receptor in regulation of vascular MCP-1, IL-6, PAI-1, MAP kinase, and matrix expressions in obesity. Kidney Int 68:2787–2793.
   PubMed Web of Science ®Google Scholar
• Walker AB, Chattington PD, Buckingham RE, Williams G. (1999). The thiazolidinedione, rosiglitazone, (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 48:1448–1453.
   PubMed Web of Science ®Google Scholar
• Weis M, Heeschen C, Glassford AJ, Cooke JP. (2002). Statins have biphasic effects on angiogenesis. Circulation 105:739–745.
   PubMed Web of Science ®Google Scholar
• Xiang L, Naik JS, Abram SR, Hester RL. 2006. Chronic hyperglycemia impairs functional vasodilation via increasing thromboxane receptor-mediated vasoconstriction. Am J Physiol Heart Circ Physiol 11 Aug [Epub ahead of print].
   Google Scholar
• Xiang L, Naik JS, Hodnett BL, Hester RL. (2006). Altered arachidonic acid metabolism impairs functional vasodilation in metabolic syndrome. Am J Physiol Regul Integr Comp Physiol 290:R134–R138.
   PubMed Web of Science ®Google Scholar
• Xiang L, Naik J, Hester RL. (2005). Exercise-induced increase in skeletal muscle vasodilatory responses in obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 288:R987–R991.
   Web of Science ®Google Scholar
• Zhou Z, Rahme E, Pilote L. (2006) Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J 151:273–281.
   PubMed Web of Science ®Google Scholar